injectible lani, page-3

re: the next biotech like biota to go up In addition to the two new reports and upcoming US conference I believe that either Pfizer or Aventis is interested in in the co. Since Dr Gray and Hunter Hall and instos control 83 % of the shares the float is small so a move through $2.55 a share will be quickly followed by a move through to 3.30-3.80 a share according to the chart. This would be an ideal time for Dr Gray who has been nurturing the co to this growth stage ,with the product indications expanding and Sir Spehres in more than 130 hospitals worldwide and growing every day, to shop the co to the highest bidder. It would have to top the $4.85 a share offer by Cehalon rejected 2 years ago by the co., to appease all the shareholders. But Mayne could enter the bidding to keep this FDA approved co in native Australia as Mayne sold their hospitable divisions to concentrate and acquire more profitable higher margined oncology businesses.